Wang Xiongbao, Fang Liang, Xiao Lixiang, Zhong Guangxin, Han Minghao, Wang Bingshen, Ren Juchao, Zang Yuanwei
Department of Urology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Front Immunol. 2024 Nov 28;15:1494005. doi: 10.3389/fimmu.2024.1494005. eCollection 2024.
Lysomembrane-associated protein 1 (LAMP1), known to exhibit differential expression in various tumor types and play a crucial role in the development of tumors. Clear cell Renal Cell Carcinoma (ccRCC) is still the most common pathological type of renal carcinoma with poor prognosis. However, the expression of LAMP1 and its underlying molecular mechanism with ccRCC remain elusive.
Firstly, the expression of LAMP1 in ccRCC and its clinical significance were analyzed using various databases. Next, Weston Blot was performed to detect the expression of LAMP1 protein in cancer tissues and adjacent tissues from 60 pairs of clinical ccRCC patients. The correlation between LAMP1 expression and different clinical indicators as well as the relationship with patient prognosis was analyzed. Furthermore, molecular cell biology experiments were conducted to validate the effects of LAMP1 gene expression on cell proliferation, invasion and migration. Additionally, we investigated the impact of VHL, a key gene in renal cancer, and LC3C, an autophagy-related gene, on LAMP1 expression through molecular biology experiments to elucidate the potential underlying mechanism.
Bioinformatics analysis revealed significant underexpression of LAMP1 in ccRCC (P<0.001), which correlated with poorer prognosis. In multivariate survival analysis, LAMP1 emerged as an independent prognostic marker for overall survival(OS)(P<0.05). Analysis of cancer and paracancer tissue samples from ccRCC patients demonstrated significantly lower levels of LAMP1 in tumors compared to paracancerous tissues (P<0.001), confirming its prognostic impact. Cell functionality experiment revealed that elevated LAMP1 inhibited cell proliferation, migration, and invasion. LAMP1 expression remained unchanged during autophagy modulation but decreased with LC3C knockdown and vice versa. Notably, VHL(+) cells expressed less LAMP1 than VHL(-) cells.
These findings indicate that low expression levels of LAMP1 is associated with poor prognosis in ccRCC. Therefore, LAMP1 emerges as a novel biomarker associated with the diagnosis and prognosis of renal cancer. Furthermore, we have also described the potential mechanism of action of LAMP1 in renal cancer. LAMP1 is a promising target for the treatment of ccRCC.
溶酶体膜相关蛋白1(LAMP1)在多种肿瘤类型中呈现差异表达,并在肿瘤发展过程中发挥关键作用。透明细胞肾细胞癌(ccRCC)仍是最常见的肾癌病理类型,预后较差。然而,LAMP1在ccRCC中的表达及其潜在分子机制仍不清楚。
首先,利用各种数据库分析LAMP1在ccRCC中的表达及其临床意义。接下来,进行蛋白质免疫印迹法检测60对临床ccRCC患者癌组织和癌旁组织中LAMP1蛋白的表达。分析LAMP1表达与不同临床指标之间的相关性以及与患者预后的关系。此外,进行分子细胞生物学实验以验证LAMP1基因表达对细胞增殖、侵袭和迁移的影响。另外,我们通过分子生物学实验研究肾癌关键基因VHL和自噬相关基因LC3C对LAMP1表达的影响,以阐明潜在的作用机制。
生物信息学分析显示,LAMP1在ccRCC中显著低表达(P<0.001),这与较差的预后相关。在多因素生存分析中,LAMP1成为总生存期(OS)的独立预后标志物(P<0.05)。对ccRCC患者癌组织和癌旁组织样本的分析表明,肿瘤中LAMP1水平明显低于癌旁组织(P<0.001),证实了其预后影响。细胞功能实验表明,LAMP1表达升高抑制细胞增殖、迁移和侵袭。在自噬调节过程中,LAMP1表达保持不变,但随着LC3C基因敲低而降低,反之亦然。值得注意的是,VHL(+)细胞比VHL(-)细胞表达的LAMP1更少。
这些发现表明,LAMP1低表达与ccRCC预后不良相关。因此,LAMP1成为一种与肾癌诊断和预后相关的新型生物标志物。此外,我们还描述了LAMP1在肾癌中的潜在作用机制。LAMP1是治疗ccRCC的一个有前景的靶点。